Oncotarget Publishes Study That Points To Improvement Of Targeted Therapies For Pancreatic Cancer Patients

One of the most fatal forms of pancreatic cancer is ductal adenocarcinoma because of its poor response to current treatments. Researchers recently found new information about DNA damage repair in relation to sporadic and germline mutations. Germline mutations such as BRCA1, BRCA2, ATM and several others are commonly reported in pancreatic cancer patients. The BRCA mutations were the most prevalent. New research using targeted therapies has shown success for people with the BRCA mutations who had cancer of the breasts or ovaries. Similar treatments are currently being tested on people with pancreatic cancer. Although the results are incomplete, they look favorable so far.

What Is Pancreatic Ductal Adenocarcinoma?

PDAC is considered the deadliest human malignancy. In the United States, the overall five-year survival rate is 7.7 percent. For patients who have surgery followed by chemotherapy to treat PDAC, the five-year survival rate is 28.8 percent. In metastatic PDAC patients who received the current top chemotherapy combination, the median survival period was barely over 11 months. In another clinical trial using a different combination of drugs, the median survival period was 8.5 months. Researchers said that recent improvements may show hints of developing benefits in new targeted therapies. Past clinical trials did not show significant benefits.Pancreatic cancer is one of the top five culprits of cancer deaths in the United States. It is expected to move up the list to number two by 2030. Unfortunately, the disease is not usually discovered until it has progressed, and it often progresses fast. Screening can be difficult since PDAC is more positively related to sporadic genetic mutations rather than family history. Researchers said that only up to 10 percent of PDAC patients have a family history of pancreatic cancer.There are several diseases and syndromes that have been identified with a greater risk of developing pancreatic cancer. They include the following:

  • Hereditary breast and ovarian cancer
  • Familial atypical multiple mole melanoma
  • Hereditary pancreatitis
  • Peutz-Jeghers syndrome
  • Familial adenomatous polyposis
  • Hereditary nonpolyposis colorectal carcinoma

In addition to the BRCA1 and BRCA2 gene mutations, PALB2, ATM, CDKN2A, TP53, MSH6, MSH2 and MSH1 are the most common germline mutations associated with PDAC development risk. Germline mutations result in a deoxyribonucleic acid damage repair deficiency because of homologous recombination breaks. Deoxyribonucleic acid repair allows cancer cells to alter and survive the damages of genotoxic stress. The BRCA1 gene’s job is to signal DNA damage repair, and the BRCA2 gene is supposed to regulate RAD51 for homologous recombination. When used with chemotherapy agents, ADP-ribose and PARP inhibitors have helped induce damage repair when the DNA repair mechanism is impaired. The treatments were used in breast and ovarian cancer patients who had the BRCA1 or BRCA2 gene mutations.

Testing Targeted Therapies

The researchers referenced two previous studies using the targeted inhibitors with chemotherapy. In one study with 306 random consecutive pancreatic cancer patients, Ontario researchers did not find a significant relationship between family history of pancreatic cancer and either of the two BRCA gene mutations. Also, they did not find a positive relationship between family history of BRCA gene mutations in relation to family history of ovarian or breast cancer. None of the patients who carried BRCA gene mutations met the Ontario Ministry of Health’s requirements for familial PDAC risk, which meant that they would not have qualified for genetic testing prior to diagnosis.

In another study, researchers tried to improve their estimation abilities for detecting BRCA mutations. To do this, they chose patients whose family members had been diagnosed with pancreatic, ovarian or breast cancer. Patients also reported any other cancer diagnoses in their families. Researchers found that the strongest connection was between people who had PDAC and had a family member who was diagnosed with breast cancer. They also found that several PDAC patients had family members with colorectal cancer. However, they did not find a significant amount of PDAC patients with family members who were diagnosed with pancreatic cancer. Only about 20 percent of the patients who had PDAC in that group would have qualified for genetic testing.

In a separate study of 159 random patients who sought genetic testing on their own, there were 24 reported pathogenic mutations related to a higher risk of developing PDAC. According to several past studies, researchers have determined that the most dangerous genetic mutations are most common among people with Jewish heritage. They said that previous studies reveal the need for more extensive testing among pancreatic cancer patients. Testing could help lead to the development of more targeted therapies. As they noted in their referenced studies, combination therapies that target the BRCA gene mutations are improving. Although family history is not always a positive indicator and most pancreatic cancer cases are sporadic, researchers said that improved recruitment and screening of individuals whose family members have been diagnosed with PDAC is needed for improving future research.

About Oncotarget

Oncotarget was founded in 2010. It is an online medical journal that publishes peer-reviewed research papers and reviews. The publication is one of the few open-access journals online. It is published by Impact Journals and edited by Mikhail Blagosklonny and Andrei Gudkov. When Dr. Gudkov lived in Russia, he earned two doctoral degrees. He worked with the National Cancer Institute, the Cleveland Clinic Foundation and several other health organizations after coming to the United States. Dr. Gudkov currently serves as a chairman for Roswell Park Cancer Institute in New York. Dr. Blagosklonny also earned two doctoral degrees and serves as an oncology professor at Roswell Park Cancer Institute. He specializes in aging and cancer, and his background includes teaching at other medical facilities. Genetic discovery and targeted therapies are two areas of interest for Dr. Blagosklonny and Dr. Gudkov.When Oncotarget first started, there were weekly publications. Since the journal became so popular, Dr. Gudkov and Dr. Blagosklonny decided to issue two publications per week. The new issues are released on the Oncotarget site every Tuesday and Friday. The journal currently holds a 5.168 impact factor, which is large enough to greatly improve the reach of any cited study or review included in a publication.

Mikhail BlagosklonnyAnd How He Runs Oncotarget

Oncotarget is one of the finest medical journals in the world, and it has been run by Mikhail Blagosklonny for many years. He has created something that pushes for research into cancer as much as possible, and he knows that there are a number of people who need to read something of this scale. This article explains how the company has built a fine journal, and it shows how they review research that is offered for every reader.

#1: The Design Of The Journal

The journal has been designed to be read online only, and it is a wonderful place to learn about cancer because there is a large variety of studies that are useful for all. There are many people who will find that journal useful because it offers new perspectives on cancer, and there are many more who wish to read something that does not come from the larger medical journals.

#2: The Research

The research that has been included in the Oncotarget journal may be read online at any time, and there are many people who submit research every month. They are hoping to have their research accepted because there is not enough room in the standard journals, and that is why they are thankful for Mikhail Blagosklonny. The review panel for this journal is quite important because it provides the resources that are needed for all patients, and it helps them read about something that may be new to them. They will learn quite a lot, and they will find that it is much easier to share or print the articles.

#3: The Review Panel

The review panel is filled with fine professionals who do amazing work, and they will review each article before it is published. They will ask for edits, and they will publish when they believe that the article is perfect for them. They will continue to ask for changes until it is right, and they will help craft research that is good for everyone. Someone who has needs in the cancer field may trust Oncotarget because they know that it has been put together in the proper manner. They will be impressed because the research is thorough, and they will be pleased to see something that helps them come to a greater understanding of cancer in general.

#4: The Availability

The journal will be available to many people, and it will provide a service that many people cannot get any other way. They are hoping to learn something new, and they know that they may learn quite a lot if they begin reading. People who do their research will be pleased with the reading, and they will find new therapies and treatments they could not have thought of.It is quite simple to read Oncotarget because it provides the finest services to all those who wish to learn about cancer. They will learn something that is unique to their situation, and they may share it or print it when they are ready.

Businesses Have Success Because of Eric Lefkofsky

Eric Lefkofsky has been able to help different people in the time that he is in business. There are many different things that he has done and the majority of these cancer treatment things have been able to help people who are a part of the sales industry that they are working in.

Starting out, Eric Lefkofsky was not as successful as what he currently is. Eric Lefkofsky started out his life in Michigan in a small community. This was something that gave him his start and gave him a chance to make things better for himself. He knew that this was a great option for someone who wanted to get ahead. He was able to make things better for himself because he knew that he would never want to go back to the place that he came from even though he loved the community that he was in to learn more: http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale click here.

To get better with his career, Eric Lefkofsky knew that he had to get an education. He saw this as the most important thing and knew that he would not be able to go anywhere without an education. During the time that he was getting his education, he was still working toward success. Right out of college, he got a job that enabled him to make sure that he was doing the right thing. It was during this time that he learned he was a great salesman and that he could sell nearly anything that he wanted with the help that thehad.

Soon after graduating and working for a carpet sales company, Eric Lefkofsky began working for company Tempus. Unlike other companies that he has since been a part of, he was on the board of Tempus. This gave him insight into healthcare sales and added another level to the experience that he has. While he has still been a part of Tempus, he has branched out into other sales industries that has enabled him to grow even more of a healthcare business expertise that nearly nobody has the ability to be able to do because of the way that they are doing things.

While Eric Lefkofsky is still on the board of Tempus, he has also worked with other companies. This has allowed him the chance to make sure that he is doing things for the way that he works. He has worked with other companies and it has given him the chance to do things that are better for companies. The experience that he has led him the chance to make sure that he is doing things better for the businesses. There are many ways in which Eric Lefkofsky has been able to help different businesses and people who run them.

Groupon is a savings company that allows people the chance to make things better for themselves. It offers products and services that are at an extremely low price from what they would normally be. The website gives deals on things that may not have discounts anywhere else. People who use Groupon know that Eric Lefkofsky is running the company and that he is helping them get savings on different deals. It has given him the chance to make things better for the way that Groupon works and the way that things are given to the clients that they have on the app.